Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
- Conditions
- Arthroplasty, ReplacementThromboembolism
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5476
- Registration Number
- NCT00846807
- Locations
- 🇩🇪
1160.85.04932 Boehringer Ingelheim Investigational Site, Pfortzheim, Germany
🇫🇷1160.85.3318A Boehringer Ingelheim Investigational Site, Bois Guillaume Cédex, France
🇫🇷1160.85.3315A Boehringer Ingelheim Investigational Site, Creteil, France
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
- Conditions
- ThromboembolismArthroplasty, Replacement
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 472
- Registration Number
- NCT00847301
- Locations
- 🇩🇪
1160.84.04938 Boehringer Ingelheim Investigational Site, Wismar, Germany
🇸🇪1160.84.4603 Boehringer Ingelheim Investigational Site, Kungälv, Sweden
🇬🇧1160.84.04407 Boehringer Ingelheim Investigational Site, Yeovil, United Kingdom
BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT00846768
- Locations
- 🇳🇱
1222.26.31002 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands
🇧🇪1222.26.32008 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪1222.26.32007 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
- Conditions
- Diabetic NeuropathiesDepressive Disorder, Major
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 108
- Registration Number
- NCT00844194
- Locations
- 🇩🇪
1208.34.49001 Boehringer Ingelheim Investigational Site, Bad Mergentheim, Germany
🇩🇪1208.34.49006 Boehringer Ingelheim Investigational Site, Limburgerhof, Germany
🇩🇪1208.34.49029 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany
Safety and Tolerability of Dabigatran Etexilate in Adolescents
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT00844415
- Locations
- 🇨🇦
1160.88.00002 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1160.88.00001 Boehringer Ingelheim Investigational Site, Ottawa, Ontario, Canada
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT00826267
- Locations
- 🇺🇸
1200.44.01001 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇧🇷1200.44.12005 Boehringer Ingelheim Investigational Site, Ijui, Brazil
🇧🇷1200.44.12007 Boehringer Ingelheim Investigational Site, Natal, Brazil
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 143
- Registration Number
- NCT00824408
- Locations
- 🇨🇦
1230.5.00106 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
🇧🇸1230.5.00118 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇨🇦1230.5.00114 Boehringer Ingelheim Investigational Site, Kelowna, British Columbia, Canada
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDrug: BI 1744 CL 5 µgDrug: BI 1744 CL 10 µgDrug: BI 1744 CL 2 µg
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT00824382
- Locations
- 🇯🇵
1222.22.010 Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaraki, Japan
🇯🇵1222.22.009 Boehringer Ingelheim Investigational Site, Kamogawa, Chiba, Japan
🇯🇵1222.22.014 Boehringer Ingelheim Investigational Site, Komaki, Aichi, Japan
Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
- Conditions
- Heart Catheterization
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT00818753
- Locations
- 🇳🇱
1160.73.31003 Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands
🇳🇱1160.73.31002 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands
🇳🇱1160.73.31004 Boehringer Ingelheim Investigational Site, Alkmaar, Netherlands
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDrug: BI 1356
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 245
- Registration Number
- NCT00819091
- Locations
- 🇮🇳
1218.35.91003 Boehringer Ingelheim Investigational Site, Aligarh, Uttar Pradesh, India
🇮🇳1218.35.91006 Boehringer Ingelheim Investigational Site, Pune, Maharastra, India
🇵🇱1218.35.48003 Boehringer Ingelheim Investigational Site, Poznan, Poland